// App-Quantinova.ai

Filters

Biomarkers











Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease











Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























1671 Abstracts

Angiographic Observations Derived From CT Cavernosography

James Trussler - New England Section of the American Urological Association (NEAUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

CT Cavernosography: a Patient-Centered Approach to Understanding Functional Penile Abnormalities

Diana Aponte-Colon - New England Section of the American Urological Association (NEAUA) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

THE ROLE OF THE CIRCULATING TUMOR CELLS IN THE SOLITARY PULMONARY NODULES

HUI XIAO - Asian Pacific Society of Respirology (APSR) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

An investigator sponsored phase Ia/Ib trial of selinexor in combination with irinotecan in patients with adenocarcinoma of stomach and distal esophagus.

Heloisa P. Soares - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Irinotecan

Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients.

Howard I. Scher - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

taxane

Circulating tumor cell (CTC) detection, N-terminal androgen (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC).

Shidong Jia - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Androgen Tear

Fractionated dose radiolabeled anti−prostate specific membrane antigen (PSMA) radioimmunotherapy (177Lu−J591) for progressive metastatic castration−resistant prostate cancer (mCRPC).

Jaspreet S. Batra - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

J591

A phase II study of cabozantinib in metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases (VM) with very small nuclear circulating tumor cell (vsnCTC) association studies.

Richard Huynh - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Cabozantinib

A phase 2 study of BIND-014 (PSMA-targeted docetaxel nanoparticle) administered to patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).

Karen A. Autio - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

Somatic mutation detection from liquid biopsy-derived cellular aggregates formed by magnetic 3D bioprinting.

Hubert Tseng - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Clinical validation of CTC subtype frequency to prognosis OS in mCRPC patients.

Ryan Vance Dittamore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

taxane

Interrogating metastatic prostate cancer treatment switch decisions.

David Lorente - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

A phase I/II study of the investigational drug alisertib in combination with abiraterone and prednisone (AP) for patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on abiraterone.

Jianqing Lin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

CB-7598

The use of whole genome copy number variation (CNV) to measure genomic instability in mCRPC CTCs.

Yipeng Wang - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

N/A

Ex vivo propagation and characterization of circulating tumor cell clusters from late stage prostate cancer patients.

James Lim - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

N/A

The Irish Programme for Stratified Prostate Cancer Therapy (iPROSPECT).

John Patrick Greene - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Prostate cancer

Androgen Tear

Implementing a CTC-based clinical trial assay for selecting AR-V7+ patients for enrollment in a pivotal phase 3 study (ARMOR3-SV).

Daniel T. Dransfield - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) and white blood cells (WBCs) in muscle invasive and metastatic bladder cancer patients.

Archana Anantharaman - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

N/A

Isolation and analysis of circulating tumor cell samples from both spiked analytical sources and patients with renal cell cancer and prostate cancer.

Robert J. Amato - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

N/A

Heterozygous CTC1 Variants in Acquired Bone Marrow Failure

Wenyi Shen - American Society of Hematology (ASH) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Aplastic anemia

N/A

Copyright © 2026. QuantiNova All rights reserved